Tuesday, 17 Sep 2019

You are here

Azathioprine Adverse Events Associated with TPMT Polymorphisms

Azathioprine (AZA) is widely used in the treatment of several autoimmune diseases. Its use and optimal dosing may be limited by adverse drug reactions (ADRs). Thiopurine S-methyltransferase (TPMT) is an important enzyme involved in AZA metabolism.

AZA is a pro-drug that is rapidly converted into 6-mercaptopurine (6-MP) via a glutathione-dependent process. TPMT is an important cytoplasmic enzyme catalyzing the methylation of 6-MP leading to the active metabolite 6-TGN.. 

Approximately 4%-11% of individuals are heterozygous for a mutant TPMT allele and have intermediate TPMT activity. Fewer (approximately 1 in 300) will be homozygous or compound heterozygous and have very low or absent TPMT activity. Individuals with intermediate TPMT activity accumulate 50% more 6-TGNs when compared with normal or high TPMT activity and thus at increased risk of AZA-induced ADRs. Patients with deficient TPMT activity rapidly accumulate high doses of 6-TGNs, and are at risk for major bone marrow toxicity.

Although several clinical guidelines recommend determining TPMT genotype or phenotype before initiating AZA therapy, there is no consensus on this issue.  Hence, a metanalysis of 11 published studies and 651 patients with autoimmune diseases studied the associations between AZA TPMT polymorphisms and ADRs.

Of the 384 patients analyzed, 101 patients had ADRs - 14.9% of ADR+ patients were TPMT polymorphism positive and 6.4%  of the 283 no-ADR patients were TPMT polymorphisms positive. TPMT polymorphisms were significantly associated with AZA-induced overall ADRs (OR 3.12; 96%CI 1.48–6.56), bone marrow toxicity (3.76; 1.97–7.17) and gastric intolerance (6.43; 2.04–20.25). These findings were strongest in asians rather than caucasians.  TPMT polymorphisms were not associated with hepatotoxicity.

These studies included patiens with both heterozygous and homozygous TPMT polymorphisms. But, subanalyses indicated that TPMT heterosigosity was also associated with AZA-induced overall bone marrow toxicity.

While a TPMT polymorphism may be associated with an increased risk of AZA-induced ADRs, the presence of normal TPMT genotypes does not preclude the development of ADRs during AZA treatment. TPMT polymorphism explains a variable proportion of AZA-related ADRs, but in no way explain all episodes of ADRs.  Therefore, laboratory monitoring remains an essential measure to ensure AZA safety.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.